Jinnette Abbott, MD
Interventional Cardiology · Providence, RINPI 1144241613
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (59.2%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 12 manufacturers reported payments, led by Abbott at 49.3% of the total. Reporting peaked in 2022 at $58,530 and has fallen 65.3% since, to $20,313 in 2025. Among interventional cardiology clinicians in RI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 151 payments — averaging $1032.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$77K
- Medtronic$50K
- Penumbra, Inc.$10K
- Boston Scientific$9K
- Philips North America LLC$5K
- Shockwave Medical, Inc$4K
- plus $1K from 6 others
Across 91 payments — averaging $3109.77 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abbott$61K
- M.a. Med Alliance S.A.$59K
- Boston Scientific$52K
- Shockwave Medical, Inc$30K
- CSL Behring$26K
- Cardiovascular Systems Inc.$15K
- plus $41K from 4 others
What the payments were for
- Consulting fees$92,30659%
- Speaking & faculty fees$45,96329%
- Travel & lodging$11,3847%
- Food & beverage$4,9383%
- Education$1,0501%
- Entertainment$2260%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 53 | $76,856 |
| Medtronic | 62 | $50,480 |
| Penumbra, Inc. | 5 | $9,766 |
| Boston Scientific | 9 | $9,277 |
| Philips North America LLC | 8 | $4,677 |
| Shockwave Medical, Inc | 5 | $3,796 |
| Abiomed | 4 | $375 |
| Terumo Medical Corporation | 1 | $250 |
| Opsens Inc. | 1 | $226 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $122 |
| Edwards Lifesciences | 1 | $25 |
| Cardiovascular Systems Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OPTIS$46,021
- ONYX FRONTIER$29,934
- HI-TORQUE BALANCE$15,750
- DRAGONFLY OPSTAR$13,614
- Indigo System$9,766
- RESOLUTE ONYX$7,091
- GENERAL BALLOONS$5,500
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$3,283
- GENERAL VASCULAR ACCESS$2,250
- US Und$1,925
- Spectranetics Undiv$1,400
- AVVIGO Guidance System$1,338
- MRI Equip Undiv$1,050
- Resolute$675
- Vascular Lithotripsy$513
- Impella$316
- Glidesheath$250
- OptoWire$226
- (6581) Verrata Plus$147
- XIENCE SIERRA$141
How this compares
$155,867 in reported general payments places this provider in the 95th percentile of 23 interventional cardiology providers in Rhode Island.
See all interventional cardiology providers in Rhode Island →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 158 | $175,426 |
| EntrestoSacubitril/Valsartan | 86 | $116,765 |
| JardianceEmpagliflozin | 93 | $109,881 |
| XareltoRivaroxaban | 58 | $71,774 |
| Repatha SureclickEvolocumab | 44 | $48,036 |
| BrilintaTicagrelor | 24 | $20,241 |
| VascepaIcosapent Ethyl | 25 | $13,012 |
| Icosapent Ethyl | 29 | $7,634 |
| Atorvastatin Calcium | 454 | $6,427 |
| Metoprolol Succinate | 404 | $5,990 |
| Rosuvastatin Calcium | 264 | $5,036 |
| Ezetimibe | 124 | $3,376 |
| ClopidogrelClopidogrel Bisulfate | 183 | $3,280 |
| Losartan Potassium | 228 | $2,793 |
| Ranolazine ErRanolazine | 17 | $2,327 |
Paid to pharmacies, not to this prescriber.
Other interventional cardiology in Providence
- Peter SoukasProvidence$798K
- Marwan SaadProvidence$57K
- Hafiz ImranProvidence$18K
- Paul GordonProvidence$13K
- Omar HyderProvidence$9K
- Anum AsifProvidence$6K
- Ahmed ElkaryoniProvidence$3K
- Barry SharafProvidence$3K
- Mitchel SklarProvidence$2K
- Saraschandra VallabhajosyulaProvidence$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.